Virginia Tech
Blacksburg, Virginia, 24060, United States
Location status: Recruiting
NCT Number: NCT07457710
Individuals with Parkinson's Disease (PD) often have motor difficulties that can negatively impact daily activities and their quality of life. Research has shown that to slow the progression of these symptoms, patients should partake in effective physical rehabilitation. However, effective physical rehabilitation has many barriers, including timing, cost, and other personal or system-level challenges. The purpose of this study is to evaluate the haptic remote rehabilitation system for patients with PD using a randomized controlled trial (RCT) in a field environment.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Blacksburg, Virginia, 24060, United States
Location status: Recruiting
Parkinson's disease (PD) is a progressive disorder that affects the central nervous system, causing unintended or uncontrollable movements. PD is the second most common neurodegenerative disease, affecting 1-2 per 1000 of the population. This prevalence has more than doubled from 2.5 million patients in 1990 to 6.1 million patients in 2016. Upcoming shifts toward an aging population will exacerbate this problem and the healthcare burden. People with PD suffer from diverse motor symptoms (e.g., tremors, rigidity, and dystonia) that adversely affect their daily activities and quality of life. Physical rehabilitation can improve motor symptoms by slowing disease progression, thereby enhancing the well-being of those with PD. However, administering physical rehabilitation in an accessible and affordable way has been quite challenging because of person- and system-level barriers to healthcare services. Visits to physical therapists, in particular, require resources supported by a caregiver and one-on-one time with specialists, both of which are costly. These problems are especially prominent for patients in rural areas, thereby serving as a major barrier to equity in access to public health assets.
At-home, technology-based rehabilitation programs could reduce training costs and enhance training accessibility, such as by removing the need for a PD patient to visit a facility in person or to schedule one-on-one therapist time. In particular, patients have responded positively to remote rehabilitation programs (e.g., through Zoom) as an alternative to in-person therapy. As these remote programs do not require special equipment other than a device for video-conferencing software, they are more accessible to broad user populations. Yet, such remote programs lack important components of usual physical rehabilitation - especially motion guidance, assessment, and feedback - during which critical communications are needed between the therapist and patient that include hands-on interactions. Also, such programs still require one-on-one therapist time, which can be costly and not affordable for long-term participation. To overcome such problems, rehabilitation systems using emerging technologies have been explored, including robotics and virtual reality (VR). Current robotics systems, though, are limited to clinical use due to their cost and size. VR-based rehabilitation programs can be good alternatives, but are still expensive and cumbersome to use, and they can cause motion sickness for PD patients. There is thus a clear need for remote rehabilitation programs that are effective, low-cost, easy to use, provide hands-on assistance, and ensure the safety of PD patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will receive a custom-made handheld haptic device, which will be used to perform selected movement tasks. The device can generate the feeling of directional feedback.
Participants will receive a handheld device similar to the haptic group. However, the device in this intervention will not provide any haptic feedback.
Time frame: At the end of the trial in week 8
This scale evaluates participants' perceived usability of the device and the haptic feedback. It consists of 10 items, each scored on a 5-point Likert scale (0-4). The total raw score is converted to a scale of 0-100. A higher score will indicate better usability. A score of 68 is considered average usability. Scores above 68 reflect above average usability, while scores below 68 reflect below-average usability.
Time frame: From enrollment to the end of intervention at 8 weeks
Each handheld device (both with and without haptic) are equipped with Intertial Measurement Units (IMUs). The data from the IMUs will be used to measure the movement accuracy, speed, and smoothness of the arm. Data recording will start during enrollment as baseline. Whenever participants complete any sessions during the 8-week trial period, data from the IMUs will be recorded to calculate movement accuracy, speed, and smoothness. We will compare these measures across the trial period to determine performance changes in the participants.
Time frame: At the end of the trial in week 8
This scale evaluates participants' expectations about exercise outcomes, including both perceived benefits and perceived negative consequences. It consists of 13 statements rated on a 5-point Likert scale from 1 (strongly disagree) to 5 (strongly agree). Items can be summarized as two subscales: positive outcome expectations (9 items; e.g., improved mood, strength, endurance) and negative outcome expectations (4 items; e.g., avoiding exercise due to shortness of breath, pain, fear of falling, or perceived cardiac stress). For scoring, item ratings are typically summed and divided by the number of items answered to yield a mean score ranging from 1 to 5. Higher scores indicate stronger outcome expectations. Higher positive-subscale scores reflect greater perceived benefits of exercise, whereas higher negative-subscale scores reflect stronger negative expectations/avoidance concerns about exercise.
Time frame: At the end of the trial in week 8
This scale evaluates participants' confidence in their ability to engage in regular physical activity and to overcome common barriers to exercise. It consists of 5 items rated on a 4-point Likert scale from 1 (not at all true) to 4 (exactly true). Items reflect perceived capability to persist with exercise, find ways to be active, achieve exercise goals, and manage barriers (e.g., fatigue or other challenges). For scoring, item ratings are typically summed (range: 5-20) or averaged (range: 1-4). Higher scores indicate greater exercise-related self-efficacy (i.e., stronger confidence in one's ability to be physically active despite obstacles).
Time frame: At baseline (Week 0)
This questionnaire includes 8 items representing key domains impacted by Parkinson's disease (mobility, activities of daily living, emotional well-being, stigma, social support/relationships, cognition/concentration, communication, and bodily discomfort). Each item asks how often the participant experienced a problem "during the last month" and is rated on a 5-point response scale: Never, Occasionally, Sometimes, Often, and Always or cannot do at all, and scored from 0 to 4. Item scores are summed to produce a raw total (range: 0-32), which is converted to a 0-100 summary index by dividing by the maximum possible score and multiplying by 100. Higher PDQ-8 scores indicate worse health-related quality of life (i.e., more frequent or severe impacts of Parkinson's disease on daily functioning and well-being).
Contact information is provided by the study sponsor or research team.
Shafiqul Islam, Ph.D.
CONTACT
Sol Lim, Ph.D.
CONTACT
Virginia Polytechnic Institute and State University
Other
Enhancing Parkinson's Disease Rehabilitation Through Remote Haptic Guidance: Field Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07734181
Basal Ganglia Diseases, Brain Diseases
Arlesheim, Basel-Landschaft, Switzerland
View Trial DetailsNCT07730073
Basal Ganglia Diseases, Brain Diseases
Kâğıthane, Istanbul, Turkey (Türkiye)
View Trial DetailsNCT07630545
Basal Ganglia Diseases, Brain Diseases
Adelaide, Australia
View Trial DetailsNCT07284784
Basal Ganglia Diseases, Brain Diseases
Birmingham, Alabama, United States
View Trial Details